Oncology company Mirati Therapeutics Inc (NASDAQ:MRTX) revealed on Tuesday the start of treatment of the first patient under its Phase 1/2 clinical trial of MRTX849 against KRAS G12C-positive advanced solid tumours.
The company added MRTX849 is an investigational KRAS G12C inhibitor for patients with advanced solid tumours that harbor KRAS G12C mutations. MRTX849 is an investigational, orally-available small molecule that is designed to potently and selectively inhibit a form of KRAS which harbors a substitution mutation (G12C).
Additionally, the KRAS G12C mutations are present in 14% of NSCLC adenocarcinoma patients, 4% of colorectal cancer patients and subsets of other types of cancer. tumours characterized by these mutations are associated with poor prognosis and resistance to therapy and these patients have few treatment options, said the company.
Under the Phase 1/2 clinical trial, the company will evaluate MRTX849 as a single agent in patients with advanced solid tumours that harbor KRAS G12C mutations. The Phase 1 dose escalation phase of the trial will assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MRTX849 in patients with molecularly-identified KRAS G12C-positive advanced solid tumours. A dose expansion phase is planned to follow the selection of a recommended Phase 2 dose.
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Flamingo Therapeutics names new director
Merck reports lung cancer trial failed to meet endpoints
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886
University of Saskatchewan Partners with SOPHiA GENETICS in landmark ovarian cancer trial